Autores: Beytullah Yildirim, Candan Tuncer, Meltem Ergun, Selahattin Unal
DEAR EDITOR: Venlafaxine-induced hepatotoxicity with notably high levels of cholestasis enzymes has rarely been described. Presence of increased cholestasis parameters in a patient with ulcerative colitis (UC) may mimic primary sclerosing cholangitis (PSC). We present here the first case of hepatotoxicity with a prominent increase in the cholestatic enzyme serum level in a patient with UC after Venlafaxine administration. A 55-year-old man who had a history of UC, pancolitis type, was admitted to our hospital with complaints of appetite loss, malaise and abdominal pain, on February 15, 2006. He has been treated with mesalazine in different doses of 2 to 3 g/day for the last three years. Venlafaxine 150 mg/day which was started after psychiatric consultation two months ago while the serum transaminase levels were normal. He has had two attacks and has been treated with steroids.
2009-11-27 | 1,009 visitas | Evalua este artículo 0 valoraciones
Vol. 8 Núm.3. Julio-Septiembre 2009 Pags. 271-272 Ann Hepatol 2009; 8(3)